Analyst Price Targets — INO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 14, 2025 1:11 pm | Edward Tenthoff | Piper Sandler | $6.00 | $1.99 | StreetInsider | 'Inovio Pharmaceuticals (INO) Raises $28.75M to Fund Operations'; PT Raised at Piper Sandler |
| August 9, 2024 6:26 am | Gregory Renza | RBC Capital | $8.00 | $8.71 | StreetInsider | Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital |
| May 14, 2024 10:08 am | Hartaj Singh | Oppenheimer | $40.00 | $11.45 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO) |
| May 13, 2024 4:32 pm | Sudan Loganathan | Stephens | $20.00 | $11.36 | TheFly | Inovio initiated with an Overweight at Stephens |
| January 25, 2024 6:57 am | Hartaj Singh | Oppenheimer | $4.00 | $6.79 | StreetInsider | Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform |
Latest News for INO
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its first quarter 2026 financial results will be released after the market close on May 13th, 2026.
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 26-cv-00803, is on behalf of a class consisting of all persons and entities other…
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. So what: If you purchased Inovio securities during the Class Period you may be entitled to compensation…
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). Inovio is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.